Safety of first line therapy drugs in multiple sclerosis in terms of pregnancy Review article
Article Sidebar
Published:
Jun 30, 2017
Keywords:
first-line drugs, pregnancy, safety
Main Article Content
Abstract
The safety of immunomodulatory therapy of MS patients at reproductive age is an important issue as it may affect pregnancy planning, conception, pregnancy history and the foetus. Numerous analyses confirm no negative pregnancy effects of injection immunomodulatory first line drugs and they may be perceived more liberally due to their high safety level. Preliminary data concerning new oral drugs is also optimistic, but it has to be confirmed.
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Ferrero S., Pretta S., Ragni N.: Multiple sclerosis: Management issues during pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2004; 115: 3-9.
2. Boskovic R., Wide R., Wolpin J. et al.: The reproductive effects of beta interferon therapy in pregnancy: A longitudinal cohort. Neurology 2005; 65: 807-811.
3. Sandberg-Wollheim M., Frank D., Goodwin T.M. et al.: Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005; 65: 802-806.
4. Coyle P.K., Roberts S., Scheuerle A. et al.: The Betaseron (Interferon Beta-1b) Pregnancy Registry. Int. J. MS Care 2010; 12: 26-28.
5. Foulds P., Richman S., Glick G. et al.: Pregnancy outcomes from the Avonex® (interferon beta-1a) pregnancy exposure registry. Mult. Scler. 2010; 16: 894-896.
6. Lu E., Wang B.W., Guimond C. et al.: Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology 2012; 79: 1130-1135.
7. Amato M.P., Portaccio E., Ghezzi A. et al.: Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology 2010; 75: 1794-1802.
8. Hale T.W., Siddiqui A.A., Baker T.E.: Transfer of interferon b-1a into human breastmilk. Breastfeed Med. 2012: 7: 123-125.
9. Avonex. Summary of product characteristics [online].
10. Rebif. Summary of product characteristics [online].
11. Betaferon. Summary of product characteristics [online].
12. Copaxone (galtiramer acetate). Summary of product characteristic [online].
13. Coyle P., Johnson K., Pardo L.: Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Neurology 2003; 60: 60-62.
14. Fragoso Y.D., Finkelsztejn A., Kaimen-Maciel D.R. et al.: Long term use of glatiramer acetate by 11 pregnant women with multiple sclerosis; a retrospective, multicentre case series. CNC Drugs 2010; 24: 969-976.
15. Salminen H.J., Leggett H., Boggild M.: Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J. Neurol. 2010; 257: 2020-2023.
16. Giannini M., Portaccio E., Ghezzi A. et al.: Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012; 12: 124-126.
17. Neudorfer O., Baruch P., Pery S.: Effect of exposure to branded glatiramer acetate during pregnancy on rates of pregnancy loss. Prezentacja: ECTRIMS 2016; plakat 1226.
18. Neudorfer O., Sandberg-Wolheim M., Coyle P.K.: The branded glatiramer acetate pregnancy database. Prezentacja: ECTRIMS 2015; plakat 1507.
19. Neudorfer O., Baruch P., Kolodny S. et al.: Pregnancy outcomes in patients with MS expose to branded glatiramer acetate. Prezentacja: AAN 2017; plakat 1.365.
20. Queiber-Wahrendorf A., Neumann D., Adamus E.: Early childhood development up to kindergarten age after glatiramer acetate exposure during early pregnancy in women with multiple sclerosis. Prezentacja: AAN 2017; plakat 1.348.
21. Hellwig K., Gold R.: Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J. Neurol. 2011; 258: 502-503.
22. Tekwidera (dimethyl fumarate). Summary of product characteristic [online].
23. Gold R.J., Phillips J.T., Havrdova E. et al.: Delayed-release demethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol. Ther. 2015; 4: 93-104.
24. Li J., Fox R., Phillips J. et al.: Delayed-release dimethyl fumarate and pregnancy: Preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Prezentacja: ECTRIMS 2015; plakat 608.
25. Everage N.J., Liu S., Newhook T.: Pregnancy outcomes with delayed-release dimethyl fumarate: preliminary registry results. Prezentacja: ECTRIMS 2016; plakat 714.
2. Boskovic R., Wide R., Wolpin J. et al.: The reproductive effects of beta interferon therapy in pregnancy: A longitudinal cohort. Neurology 2005; 65: 807-811.
3. Sandberg-Wollheim M., Frank D., Goodwin T.M. et al.: Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005; 65: 802-806.
4. Coyle P.K., Roberts S., Scheuerle A. et al.: The Betaseron (Interferon Beta-1b) Pregnancy Registry. Int. J. MS Care 2010; 12: 26-28.
5. Foulds P., Richman S., Glick G. et al.: Pregnancy outcomes from the Avonex® (interferon beta-1a) pregnancy exposure registry. Mult. Scler. 2010; 16: 894-896.
6. Lu E., Wang B.W., Guimond C. et al.: Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology 2012; 79: 1130-1135.
7. Amato M.P., Portaccio E., Ghezzi A. et al.: Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology 2010; 75: 1794-1802.
8. Hale T.W., Siddiqui A.A., Baker T.E.: Transfer of interferon b-1a into human breastmilk. Breastfeed Med. 2012: 7: 123-125.
9. Avonex. Summary of product characteristics [online].
10. Rebif. Summary of product characteristics [online].
11. Betaferon. Summary of product characteristics [online].
12. Copaxone (galtiramer acetate). Summary of product characteristic [online].
13. Coyle P., Johnson K., Pardo L.: Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Neurology 2003; 60: 60-62.
14. Fragoso Y.D., Finkelsztejn A., Kaimen-Maciel D.R. et al.: Long term use of glatiramer acetate by 11 pregnant women with multiple sclerosis; a retrospective, multicentre case series. CNC Drugs 2010; 24: 969-976.
15. Salminen H.J., Leggett H., Boggild M.: Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J. Neurol. 2010; 257: 2020-2023.
16. Giannini M., Portaccio E., Ghezzi A. et al.: Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012; 12: 124-126.
17. Neudorfer O., Baruch P., Pery S.: Effect of exposure to branded glatiramer acetate during pregnancy on rates of pregnancy loss. Prezentacja: ECTRIMS 2016; plakat 1226.
18. Neudorfer O., Sandberg-Wolheim M., Coyle P.K.: The branded glatiramer acetate pregnancy database. Prezentacja: ECTRIMS 2015; plakat 1507.
19. Neudorfer O., Baruch P., Kolodny S. et al.: Pregnancy outcomes in patients with MS expose to branded glatiramer acetate. Prezentacja: AAN 2017; plakat 1.365.
20. Queiber-Wahrendorf A., Neumann D., Adamus E.: Early childhood development up to kindergarten age after glatiramer acetate exposure during early pregnancy in women with multiple sclerosis. Prezentacja: AAN 2017; plakat 1.348.
21. Hellwig K., Gold R.: Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J. Neurol. 2011; 258: 502-503.
22. Tekwidera (dimethyl fumarate). Summary of product characteristic [online].
23. Gold R.J., Phillips J.T., Havrdova E. et al.: Delayed-release demethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol. Ther. 2015; 4: 93-104.
24. Li J., Fox R., Phillips J. et al.: Delayed-release dimethyl fumarate and pregnancy: Preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Prezentacja: ECTRIMS 2015; plakat 608.
25. Everage N.J., Liu S., Newhook T.: Pregnancy outcomes with delayed-release dimethyl fumarate: preliminary registry results. Prezentacja: ECTRIMS 2016; plakat 714.